secwatch.observer — SEC 8-K summary
======================================

Issuer:     Embecta Corp. (EMBC)
CIK:        0001872789
Form:       8-K
Filed at:   2022-04-06T23:59:59+00:00
Accession:  0001193125-22-097622
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.03, 5.02, 5.03, 5.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Embecta completes spin-off from BD, lists on NASDAQ as EMBC with $1.65B in new debt
--------------------------------------------------------------------------------

- Spin-off effective April 1, 2022; shares distributed to BD stockholders; EMBC listed on Nasdaq.
- Embecta is the largest diabetes injection device producer, making ~8B devices/yr for ~30M patients across 100+ countries.
- Entered $500M revolver, $950M term loan B, and $200M 6.75% senior secured notes due 2030 to fund separation and operations.
- Appointed Devdatt Kurdikar as CEO, Jacob Elguicze as CFO, and other executive officers; board expanded to nine directors.
- Estimates insulin delivery market at $6-8B annually; manufacturing footprint of ~800K sq ft in US, Ireland, and China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1872789/000119312522097622/0001193125-22-097622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1872789/000119312522097622/d297684d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-097622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer